Caris Life Sciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	812.03	412.26	306.13	258.49
Revenue Growth (YoY)	96.97%	34.67%	18.43%	-
Cost of Revenue	272.87	233.48	216.82	178.46
Gross Profit	539.17	178.78	89.31	80.02
Selling, General & Admin	392.47	491.37	441.03	294.51
Research & Development	101.58	113.92	116.88	101.27
Total Operating Expenses	494.06	605.29	557.91	395.78
Operating Income	45.11	-257.12	-319.55	-315.76
Interest Income	16.5	7.12	11.26	0.95
Interest Expense	-56.85	-50.03	-31.61	-26.68
Other Non-Operating Income (Expense)	-72.85	18.14	-1.51	20.66
Total Non-Operating Income (Expense)	-113.2	-24.77	-21.86	-5.07
Pretax Income	-68.09	-281.89	-341.42	-320.83
Net Income	-68.09	-378.26	-462.53	-320.83
Net Income Attributable to Preferred Dividends	-	96.37	121.11	-
Net Income to Common	-68.09	-378.26	-462.53	-320.83
Shares Outstanding (Basic)	167	35	35	0
Shares Outstanding (Diluted)	167	35	35	0
Shares Change (YoY)	371.04%	1.59%	104626.23%	-
EPS (Basic)	-3.22	-10.66	-13.24	-12.00
EPS (Diluted)	-3.22	-10.66	-13.24	-12.00
Free Cash Flow	66.9	-253.64	-298.42	-327.96
Free Cash Flow Per Share	0.40	-7.15	-8.54	-9829.27
Gross Margin	66.40%	43.37%	29.17%	30.96%
Operating Margin	5.56%	-62.37%	-104.38%	-122.16%
Profit Margin	-8.38%	-68.38%	-111.53%	-124.12%
FCF Margin	8.24%	-61.53%	-97.48%	-126.88%
EBITDA	67.73	-208.21	-270.55	-267.5
EBITDA Margin	8.34%	-50.50%	-88.38%	-103.49%
EBIT	45.11	-257.12	-319.55	-315.76
EBIT Margin	5.56%	-62.37%	-104.38%	-122.16%

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q